|
1
|
El Atiq F, Garrouste F, Remacle-Bonnet M,
Sastre B and Pommier G: Alterations in serum levels of insulin-like
growth factors and insulin-like growth-factor-binding proteins in
patients with colorectal cancer. Int J Cancer. 57:491–497. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Karasik A, Menczer J, Pariente C and
Kanety H: Insulin-like growth factor-I (IGF-I) and IGF-binding
protein-2 are increased in cyst fluids of epithelial ovarian
cancer. J Clin Endocrinol Metab. 78:271–276. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Baron-Hay S, Boyle F, Ferrier A and Scott
C: Elevated serum insulin-like growth factor binding protein-2 as a
prognostic marker in patients with ovarian cancer. Clin Cancer Res.
10:1796–1806. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee DY, Kim SJ and Lee YC: Serum
insulin-like growth factor (IGF)-I and IGF-binding proteins in lung
cancer patients. J Kor Med Sci. 14:401–404. 1999. View Article : Google Scholar
|
|
5
|
Cohen P, Peehl DM, Stamey TA, Wilson KF,
Clemmons DR and Rosenfeld RG: Elevated levels of insulin-like
growth factor-binding protein-2 in the serum of prostate cancer
patients. J Clin Endocrinol Metab. 76:1031–1035. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shariat SF, Lamb DJ, Kattan MW, Nguyen C,
Kim J, Beck J, Wheeler TM and Slawin KM: Association of
preoperative plasma levels of insulin-like growth factor I and
insulin-like growth factor binding proteins-2 and −3 with prostate
cancer invasion, progression and metastasis. J Clin Oncol.
20:833–841. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Busund LT, Richardsen E, Busund R, Ukkonen
T, Bjørnsen T, Busch C and Stalsberg H: Significant expression of
IGFBP2 in breast cancer compared with benign lesions. J Clin
Pathol. 58:361–366. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
So AI, Levitt RJ, Eigl B, Fazli L,
Muramaki M, Leung S, Cheang MC, Nielsen TO, Gleave M and Pollak M:
Insulin-like growth factor binding protein-2 is a novel therapeutic
target associated with breast cancer. Clin Cancer Res.
14:6944–6954. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schütt BS, Langkamp M, Rauschnabel U,
Ranke MB and Elmlinger MW: Integrin-mediated action of insulin-like
growth factor binding protein-2 in tumor cells. J Mol Endocrinol.
32:859–868. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pereira JJ, Meyer T, Docherty SE, Reid HH,
Marshall J, Thompson EW, Rossjohn J and Price JT: Bimolecular
interaction of insulin-like growth factor (IGF) binding protein-2
with alphavbeta3 negatively modulates IGF-I-mediated migration and
tumor growth. Cancer Res. 64:977–984. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang C, Gao C, Meng K, Qiao H and Wang Y:
Human adipocytes stimulate invasion of breast cancer MCF-7 cells by
secreting IGFBP-2. PLoS One. 10:e01193482015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zaiss AK and Muruve DA: Immunity to
adeno-associated virus vectors in animals and humans: A continued
challenge. Gene Ther. 15:808–816. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Herzog RW, Yang EY, Couto LB, Hagstrom JN,
Elwell D, Fields PA, Burton M, Bellinger DA, Read MS, Brinkhous KM,
et al: Long-term correction of canine hemophilia B by gene transfer
of blood coagulation factor IX mediated by adeno-associated viral
vector. Nat Med. 5:56–63. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang L, Takabe K, Bidlingmaier SM, Ill CR
and Verma IM: Sustained correction of bleeding disorder in
hemophilia B mice by gene therapy. Proc Natl Acad Sci USA. 96:pp.
3906–3910. 1999; View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ponnazhagan S, Mahendra G, Kumar S, Shaw
DR, Stockard CR, Grizzle WE and Meleth S: Adeno-associated virus
2-mediated antiangiogenic cancer gene therapy: Long-term efficacy
of a vector encoding angiostatin and endostatin over vectors
encoding a single factor. Cancer Res. 64:1781–1787. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Collins SA, Buhles A, Scallan MF, Harrison
PT, O'Hanlon DM, O'Sullivan GC and Tangney M: AAV2-mediated in vivo
immune gene therapy of solid tumours. Genet Vaccines Ther. 8:82010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Alam S, Bowser BS, Conway MJ, Israr M,
Tandon A and Meyers C: Adeno-associated virus type 2 infection
activates caspase dependent and independent apoptosis in multiple
breast cancer lines but not in normal mammary epithelial cells. Mol
Cancer. 10:972011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Foulstone EJ, Zeng L, Perks CM and Holly
JM: Insulin-like growth factor binding protein 2 (IGFBP-2) promotes
growth and survival of breast epithelial cells: Novel regulation of
the estrogen receptor. Endocrinology. 154:1780–1793. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang C, Bian Z, Wei D and Zhang JG:
MiR-29b regulates migration of human breast cancer cells. Mol Cell
Biochem. 352:197–207. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Uzoh CC, Holly JM, Biernacka KM, Persad
RA, Bahl A, Gillatt D and Perks CM: Insulin-like growth
factor-binding protein-2 promotes prostate cancer cell growth via
IGF-dependent or -independent mechanisms and reduces the efficacy
of docetaxel. Br J Cancer. 104:1587–1593. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Holmes KM, Annala M, Chua CY, Dunlap SM,
Liu Y, Hugen N, Moore LM, Cogdell D, Hu L, Nykter M, et al:
Insulin-like growth factor-binding protein 2-driven glioma
progression is prevented by blocking a clinically significant
integrin, integrin-linked kinase, and NF-κB network. Proc Natl Acad
Sci USA. 109:pp. 3475–3480. 2012; View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kiepe D, Van Der A, Ciarmatori S, Ständker
L, Schütt B, Hoeflich A, Hügel U, Oh J and Tönshoff B: Defined
carboxy-terminal fragments of insulin-like growth factor (IGF)
binding protein-2 exert similar mitogenic activity on cultured rat
growth plate chondrocytes as IGF-I. Endocrinology. 149:4901–4911.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang GK, Hu L, Fuller GN and Zhang W: An
interaction between insulin-like growth factor-binding protein 2
(IGFBP2) and integrin alpha5 is essential for IGFBP2-induced cell
mobility. J Biol Chem. 281:14085–14091. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sehgal P, Kumar N, Praveen Kumar VR, Patil
S, Bhattacharya A, Vijaya Kumar M, Mukherjee G and Kondaiah P:
Regulation of protumorigenic pathways by insulin like growth factor
binding protein2 and its association along with β-catenin in breast
cancer lymph node metastasis. Mol Cancer. 12:632013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chakrabarty S and Kondratick L:
Insulin-like growth factor binding protein-2 stimulates
proliferation and activates multiple cascades of the
mitogen-activated protein kinase pathways in NIH-OVCAR3 human
epithelial ovarian cancer cells. Cancer Biol Ther. 5:189–197. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chatterjee S, Park ES and Soloff MS:
Proliferation of DU145 prostate cancer cells is inhibited by
suppressing insulin-like growth factor binding protein-2. Int J
Urol. 11:876–884. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Miyake H, Hara I, Yamanaka K, Muramaki M,
Gleave M and Eto H: Introduction of insulin-like growth factor
binding protein-2 gene into human bladder cancer cells enhances
their metastatic potential. Oncol Rep. 13:341–345. 2005.PubMed/NCBI
|
|
28
|
Fukushima T, Tezuka T, Shimomura T, Nakano
S and Kataoka H: Silencing of insulin-like growth factor-binding
protein-2 in human glioblastoma cells reduces both invasiveness and
expression of progression-associated gene CD24. J Biol Chem.
282:18634–18644. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Alam S, Bowser BS, Israr M, Conway MJ and
Meyers C: Adeno-associated virus type 2 infection of nude mouse
human breast cancer xenograft induces necrotic death and inhibits
tumor growth. Cancer Biol Ther. 15:1013–1028. 2014. View Article : Google Scholar : PubMed/NCBI
|
